MDRX 11.54 Allscripts Healthcare Solutions $MDRX Hit a 52

New Post Public Reply Private Reply Replies (0) Message Board
Emylers
MDRX 11.54 Allscripts Healthcare Solutions $MDRX Hit a 52 week low of 11.00 Currently at 11.54 -2.01 -14.83% With a day low of 11.00 and a total volume of 16,963,100.

MDRX Allscripts Healthcare Solutions Recent Headline News

Nasdaq stocks posting largest percentage decreases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TNGO: 12.24 (-0.12), PRSC: 38.48 (-0.90), FNGN: 31.39 (-9.43), LACO: 6.91 (-1.23), MSON: 11.80 (-2.44), SLXP: 91.47 (-47.08), FNHC: 26.14 (+0.04), MDRX: 11.54 (-2.01), PCMI: 7.45 (-3.15), UBNT: 28.78 (-5.84), PFMT: 7.04 (-1.61), ICPT: 172.59 (-74.39), ANDE: 54.79 (+2.83), ACTA: 16.52 (+0.62)

Allscripts Healthcare Solutions Set to Possibly Rebound After Yesterday's Selloff of 14.83%
Comtex SmarTrend(R) - Fri Nov 07, 3:57PM CST
Allscripts Healthcare Solutions (NASDAQ:MDRX) traded in a range yesterday that spanned from a low of $11.00 to a high of $11.76. Yesterday, the shares fell 14.8%, which took the trading range below the 3-day low of $13.40 on volume of 16.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MDRX: 11.54 (-2.01)

Allscripts Healthcare Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 12:30PM CST
Allscripts Healthcare Solutions, Inc. (MDRX) posted adjusted earnings of 2 cents per share in the third quarter of 2014 which missed the Zacks Consensus Estimate by 3 cents.
GWPH: 73.97 (-0.41), ABAX: 51.63 (-2.21), MDRX: 11.54 (-2.01), MRGE: 3.06 (+0.03)

Allscripts Healthcare Solutions (MDRX) Stock Lower After Earnings Miss
at The Street - Fri Nov 07, 9:20AM CST
Allscripts Healthcare Solutions (MDRX) is falling Friday after missing analysts' estimates for earnings and revenue in the third quarter.
MDRX: 11.54 (-2.01)

AllScripts Healthcare reports 3Q loss
AP - Thu Nov 06, 5:44PM CST
CHICAGO (AP) — Allscripts Healthcare Solutions Inc. on Thursday posted lower-than-expected third-quarter results and the stock of the electronic health records company tumbled in extended trading.
MDRX: 11.54 (-2.01)

Allscripts announces third quarter 2014 results
PR Newswire - Thu Nov 06, 3:01PM CST
Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) ("Allscripts" today announced its financial results for the three and nine months ended September 30, 2014.
MDRX: 11.54 (-2.01)

Downtrend Call Working As Allscripts Healthcare Solutions Stock Falls 12.9% (MDRX)
Comtex SmarTrend(R) - Thu Nov 06, 9:33AM CST
SmarTrend identified a Downtrend for Allscripts Healthcare Solutions (NASDAQ:MDRX) on August 4th, 2014 at $15.49. In approximately 3 months, Allscripts Healthcare Solutions has returned 12.92% as of today's recent price of $13.49.
MDRX: 11.54 (-2.01)

Etransmedia Wins Multi-Million Dollar Award against Allscripts Healthcare in High-Profile Deceptive Business Practice Case
GlobeNewswire - Thu Nov 06, 4:56AM CST
After a hard-fought trial, Etransmedia Technology, Inc. won a decisive victory when an arbitration panel in Raleigh, North Carolina ruled that Allscripts Healthcare, LLC (NASDAQ: MDRX), with offices in Chicago, and Raleigh, NC, had breached its partner agreement with Etransmedia, and violated the North Carolina Unfair and Deceptive Trade Practices Act.
MDRX: 11.54 (-2.01)

Allscripts launches new mobile acute care solution
M2 - Thu Oct 30, 7:37AM CDT
Allscripts (NASDAQ: MDRX) said it has introduced Sunrise Mobile Care, a new mobile application for the Allscripts Sunrise EHR that delivers valuable medication, order and result information to the mobile devices of nurses and other clinicians.
MDRX: 11.54 (-2.01)

Allscripts launches new mobile acute care solution designed for nursing professionals
CNW Group - Wed Oct 29, 7:01AM CDT
Allscripts (NASDAQ: MDRX) has introduced Sunrise Mobile CareTM, a new mobile application for the Allscripts Sunrise EHR that delivers valuable medication, order and result information to the mobile devices of nurses and other clinicians.
MDRX: 11.54 (-2.01)

Cerner Sees In-Line Q3 Earnings but Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 8:50AM CDT
For the fourth quarter of 2014, Cerner Corporation (CERN) anticipates revenues between $880 and $915 million
QSII: 14.56 (-0.34), MDRX: 11.54 (-2.01), CERN: 63.01 (-0.87), ATHN: 123.82 (-1.94)

Healthcare IT Sparks Sales At Quality Systems, But Profit Drops
Todd Campbell, The Motley Fool - Motley Fool - Thu Oct 23, 8:24AM CDT
Healthcare providers appetite for technology that allows for the electrification of patient health records, practice and processes, and data analytics led to 9% year-over-year sales growth for Quality Systems in its fiscal second quarter ending...
QSII: 14.56 (-0.34), MDRX: 11.54 (-2.01)

Allscripts and ScriptSave team up to deploy innovative prescription savings program
PR Newswire - Thu Oct 23, 7:01AM CDT
Allscripts (NASDAQ: MDRX) has announced that it has partnered with prescription savings solutions provider ScriptSave to deploy innovative capabilities that can promote patient adherence.
MDRX: 11.54 (-2.01)

15.5% Return Seen to Date on SmarTrend Allscripts Healthcare Solutions Call (MDRX)
Comtex SmarTrend(R) - Tue Oct 21, 9:38AM CDT
SmarTrend identified a Downtrend for Allscripts Healthcare Solutions (NASDAQ:MDRX) on August 4th, 2014 at $15.49. In approximately 3 months, Allscripts Healthcare Solutions has returned 15.47% as of today's recent price of $13.09.
MDRX: 11.54 (-2.01)

Global Medication Management Market 2014-2019 - Systems, Services & Mode of Delivery Analysis of the $1.6 Billion Industry
M2 - Mon Oct 20, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vjmrp/medication) has announced the addition of the "Medication Management Market by Systems, Services, Mode of Delivery - Global Forecast to 2019" report to their offering. The global medication management market is valued at an estimated $845.1 million in 2014 and is expected to grow at a CAGR of 14% from 2014 to 2019, to reach $1,624.9 million by 2019 The adoption of medication management solutions by healthcare providers is increasing, owing to the rising concerns for minimizing adverse drug events and related medication errors. This is one of the key factors driving the growth of this market in the forecast period. Government initiatives to improve quality of care for patients and reduce healthcare expenditure are also expected to support the growth of the market in the coming years. The global market is broadly segmented by systems, services, mode of delivery, and end-users. The software market is divided into computerized physician order entry, clinical decision support systems, administration software, inventory management software, automated dispensing systems, and assurance systems software. The market, by services, is divided into medication analytics, point-of-care verification, and ADE (adverse drug events) surveillance. The end-users market is segmented into hospitals, pharmacies, and others. The market, by mode of delivery, is divided into on-premises, web-based, and cloud-based models. In 2013, the North American market dominated the global medication management market with a share of 63.7%, followed by Europe, APAC, and RoW. The APAC region shows the maximum growth potential in the coming few years. The urgent need for modernization of healthcare infrastructure, owing to the growth in aging population and increasing incidences of chronic diseases will help drive this market. Countries such as South Korea, China, and Singapore are expected to steer the growth of the medication management market in the APAC region. CareFusion Corporation (U.S.), McKesson Corporation (U.S.), Allscripts Healthcare Solutions, Inc. (U.S.), Cerner Corporation (U.S.), and Siemens Healthcare (Germany) are some of the top players in the global medication management market. Report Scope By Software - Computerized Physician Order Entry - Clinical Decision Support System - Administration Software - Electronic Medication Administration Record (EMAR) - Barcode Medication Administration (BMA) - Inventory Management - Automated Dispensing Systems (ADS) - Centralized - Robots - Carousels - Decentralized Automated Dispensing Systems - Pharmacy-based ADS - Ward-based ADS - Automated Unit-Dose Dispensing - Assurance System Software By Services - Medication Analytics - Point-of-Care Verification - ADE Surveillance By End-users - Hospitals - Pharmacy - Others By Mode of Delivery - On-premises - Web-based - Cloud-based Companies Mentioned - Allscripts Healthcare Solutions, Inc. - Carefusion Corporation - Cerner Corporation - GE Healthcare (A Division Of General Electric Company) - Mckesson Corporation - Meditech - Omnicell, Inc. - Optum Inc. - Quadramed Corporation - Siemens Healthcare (Subsidiary Of Siemens Ag) For more information visit http://www.researchandmarkets.com/research/9vjmrp/medication
GE: 26.41 (+0.05), MCK: 199.32 (-3.34), MDRX: 11.54 (-2.01), OMCL: 31.89 (-0.28), CERN: 63.01 (-0.87)

Allscripts FollowMyHealth Achieve now generally available; leverages consumer devices for better population health management
PR Newswire - Thu Oct 09, 7:01AM CDT
Allscripts (NASDAQ: MDRX) has announced the market launch and general availability of Allscripts FollowMyHealth(TM) Achieve, a consumer-friendly, patient engagement innovation intended to mobilize and empower patients as active partners in the management of their care.
MDRX: 11.54 (-2.01)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 26

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading

Top 5 Most Recently Viewed Articles

NuCana Discontinues Phase 2 Colorectal Cancer Study

Updated Category News Views 146

NuCana Provides Update on Phase 2 Randomized Colorectal Cancer Study NuTide:323 Study Discontinued Following Initial Analysis Ongoing Studies Show Promise with NUC-7738 and Pembrolizumab NuCana plc (NASDAQ: NCNA) has shared important updates about its clinical trials focused on innovative treatments for colorectal cancer. The company has made the decision to discontinue...

Continue Reading
Brøndbyernes IF Football Meeting - Key Highlights Recap

Updated Category News Views 179

Overview of the Annual General Meeting for Brøndbyernes IF Football A/S BRØNDBYERNES I.F. FODBOLD A/S CVR-nr. 83 93 34 10 This report summarizes the outcomes of the annual general meeting conducted by Brøndbyernes IF Football A/S. Key Date and Location The annual shareholders meeting took place, gathering stakeholders and shareholders at the club's headquarters. A...

Continue Reading
Uncovering the Wealth from Investing in BlackRock

Updated Category News Views 314

The Potential Growth of $1000 in BlackRock Investors often wonder how their money would grow over time if invested in strong companies. Recently, we looked into BlackRock, Inc., known by its stock ticker BLK. Over a span of 15 years, investing just $1000 into BlackRock stocks would yield an impressive value today. According to current evaluations, if you had made that...

Continue Reading
Zealand Pharma Advances Glepaglutide Approval for SBS Treatment

Updated Category News Views 267

Glepaglutide Submission to EMA Marks Significant Progress Zealand Pharma A/S, a pioneering biotechnology company, has recently shared exciting news about its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its innovative drug, glepaglutide. This long-acting GLP-2 analog is specifically designed for treating adults suffering from short...

Continue Reading
Seven Gables Real Estate Partners with Local Logic for Insights

Updated Category News Views 40

Seven Gables Real Estate Partners with Local Logic In a significant move that underscores their dedication to innovation, Seven Gables Real Estate has announced an exciting partnership with Local Logic, a leader in location intelligence. This collaboration is set to incorporate Local Logic's cutting-edge products—Local Content, Local Search, and NeighborhoodWrap—into...

Continue Reading